Clinical Trials on Pancreatic Adenocarcinoma Non-resectable in China

Total 354 results

First People's Hospital of Hangzhou

Completed

EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma

Pancreatic Adenocarcinoma Non-resectable

China
Wuhan Union Hospital, China

Not yet recruiting

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDAC

China
Shanghai Proton and Heavy Ion Center

Recruiting

Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer

Pancreatic Cancer Non-resectable

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Pancreatic Adenocarcinoma Resectable | Neoadjuvant Chemotherapy

China
Fudan University

Recruiting

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Cancer

China
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
Shanghai Zhongshan Hospital

Recruiting

Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study

Surgery | Resectable Pancreatic Cancer | Adjuvant Chemoradiotherapy

China
West China Hospital

Recruiting

Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Cholangiocarcinoma Non-resectable

China
BAIYONG SHEN
GeneCast Biotechnology Co., Ltd.

Completed

Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

Pancreatic Cancer Resectable

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-013)

Cholangiocarcinoma Non-resectable

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-012)

Cholangiocarcinoma Non-resectable

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (CCGLC-009)

Cholangiocarcinoma Non-resectable

China
Peking University Third Hospital
Beijing 302 Hospital; Tengzhou Central People's Hospital; Guangxi Ruikang Hospital

Unknown

I125 Seed Implantation vs Stereotactic Radiotherapy for Pancreatic Cancer (Ckvssip)

Radiotherapy | Pancreatic Cancer Non-resectable | Brachytherapy

China
Zhejiang Cancer Hospital

Recruiting

Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer

Non-Resectable Pancreas Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

HER2 Gene Mutation | Bile Duct Adenocarcinoma Non-Resectable

China
Hepatopancreatobiliary Surgery Institute of Gansu...

Recruiting

Photodynamic Therapy for Cholangiocarcinoma

Cholangiocarcinoma Non-resectable

China
BAIYONG SHEN
GeneCast Biotechnology Co., Ltd.

Not yet recruiting

ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma

Pancreatic Cancer Resectable

China
Fudan University

Unknown

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Stage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic Adenocarcinoma

China
Xian-Jun Yu

Completed

Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Stage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic Adenocarcinoma

China
Xian-Jun Yu

Completed

Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Stage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic Adenocarcinoma

China
Peking Union Medical College Hospital

Unknown

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Cancer

China
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Pancreatic Adenocarcinoma | Resectable Pancreatic Carcinoma

United States
Zhejiang Provincial People's Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Resectable Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer

Resectable Pancreatic Cancer

China
Fudan University
West China Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Zhejiang... and other collaborators

Recruiting

Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC

Borderline Resectable Pancreatic Cancer

China
Yuhong Li

Completed

Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Pancreatic Cancer Resectable

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Borderline Resectable Pancreatic Cancer

China
Health Science Center of Xi'an Jiaotong University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Recruiting

The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

Pancreatic Cancer Resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Hepatocellular Carcinoma Non-resectable

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.

Recruiting

Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-011)

Hepatocellular Carcinoma Non-resectable

China
Jinan Military General Hospital

Recruiting

The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Sorafenib and Tislelizumab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Huazhong University of Science and Technology

Unknown

Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable

China
Tianjin Medical University Cancer Institute and...

Recruiting

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Hepatocellular Carcinoma | Hepatocellular Carcinoma Non-resectable

China
FibroGen

Active, not recruiting

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer (LAPIS)

Pancreatic Cancer Non-resectable

United States, Canada, France, Germany, Spain, Korea, Republic of, Austria, Italy, China, Belgium, Israel, United Kingdom
Peking Union Medical College Hospital

Recruiting

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer (MAP-02)

Pancreatic Cancer | Resectable Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... and other collaborators

Active, not recruiting

Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC (REGSIN)

Hepatocellular Carcinoma Non-resectable

China
Xiangya Hospital of Central South University

Active, not recruiting

Thermal Ablation Followed by Immunotherapy for HCC

Hepatocellular Carcinoma Non-resectable

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

Divestment for Artery-involved Pancreatic Cancer

Pancreatic Cancer | Neoadjuvant Therapy | Borderline Resectable Pancreatic Cancer | Locally Advanced Pancreatic Cancer

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...
First People's Hospital of Foshan; Affiliated Cancer Hospital & Institute of... and other collaborators

Recruiting

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Active, not recruiting

TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

Hepatocellular Carcinoma Non-resectable

China
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Ruijin Hospital
Intuitive Surgical

Recruiting

Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors (PORTAL)

Pancreatic Adenocarcinoma | Chronic Pancreatitis | Ampullary Adenocarcinoma | Cholangiocarcinoma, Extrahepatic | Pancreatic Cysts | Pancreatic Endocrine Tumors | Duodenal Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (PLTHCC)

Hepatocellular Carcinoma Non-resectable

China
First Affiliated Hospital of Wenzhou Medical University
Qilu Hospital of Shandong University; Eastern Hepatobiliary Surgery Hospital; The First Affiliated Hospital of Zhejiang Chinese Medical University

Enrolling by invitation

Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)

Hepatocellular Carcinoma Non-resectable | Effect of Drug

China

Clinical Trials on Pancreatic Adenocarcinoma Non-resectable in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations